Ophthalmos Research and Educational Institute

Publications

Published paper : Omega-3 Polyunsaturated Fatty Acids and Their Anti-Oxidant, Anti-Inflammatory and Neuroprotective Effects in Diabetic Retinopathy. July 2023

This publication by our Reasearch team at Ophthalmos shows that dietary supplementation with omega 3 can halt and reverse the retinal damage seen in Diabetic Retinopathy Link : https://www.imrpress.com/journal/FBL/28/7/10.31083/j.fbl2807153/htm

Published paper : Omega-3 Polyunsaturated Fatty Acids and Their Anti-Oxidant, Anti-Inflammatory and Neuroprotective Effects in Diabetic Retinopathy. July 2023 Read More »

Published research paper: Kalogerou M. et al. Omega-3 fatty acids promote neuroprotection, decreased apoptosis and reduced glial cell activation in the retina of a mouse model of OPA1-related autosomal dominant optic atrophy. Exp Eye Res. Feb. 2022

These findings by Ophthalmos Research team support the use of omega-3 polyunsaturated fatty acids as a therapy for autosomal dominant optic atrophy. Omega-3 fatty acid supplementation has neuroprotective effects on the retinas of a mouse model of OPA1-related autosomal dominant optic atrophy by  blocking the inflammatory activation of astrocytes and microglia  and by suppressing the proapoptotic Bcl-2-associated X protein and caspase-3 in the retinas. https://www.sciencedirect.com/science/article/pii/S001448352100467X?dgcid=author

Published research paper: Kalogerou M. et al. Omega-3 fatty acids promote neuroprotection, decreased apoptosis and reduced glial cell activation in the retina of a mouse model of OPA1-related autosomal dominant optic atrophy. Exp Eye Res. Feb. 2022 Read More »

Publication : Prokopiou E et al. Omega-3 fatty acids supplementation protects the retina from age-associated degeneration in aged C57BL/6J mice. BMJ Open Ophthalmology 2019;4-Nov

The published paper by Ophthalmos Research team suggest that ω3 supplementation can be considered a therapeutic intervention against age-associated retinal dysfunction. The prevention of age-related loss of vision or enhancement of visual acuity in the elderly can significantly improve their quality of life, in addition to improving their function in activities of daily living.

Publication : Prokopiou E et al. Omega-3 fatty acids supplementation protects the retina from age-associated degeneration in aged C57BL/6J mice. BMJ Open Ophthalmology 2019;4-Nov Read More »

Publication : Omega-3 Fatty Acids Supplementation: Therapeutic Potential in a Mouse Model of Stargardt Disease . IOVS June 2018

Ophthalmos Research team has discovered a novel therapy for vision improvement in patients with Stargardt disease. It is one of the most common forms of macular dystrophy and to date no treatment has provided evidence of disease regression. The published paper shows how fatty acids reduced the accumulation of lipofuscin granules and A2E levels and decreased C3 level, in the retina of animal model of Stargardt disease. It also demonstrated a protective effect against photoreceptors which confirms Ophthalmos Institute observational studies for vision improvement in patients with Stargardt disease. Link : click HERE for the publication

Publication : Omega-3 Fatty Acids Supplementation: Therapeutic Potential in a Mouse Model of Stargardt Disease . IOVS June 2018 Read More »

Publication ‘Omega-3 fatty acids protect retinal neurons in glaucoma mouse model’ Exp Eye Res. Jan 2018

The Research team at Ophthalmos Institute has confirmed that Omega-3 fatty acids can protect the optic nerve in glaucoma. ‘Glaucoma is the second leading cause of irreversible blindness, and affects 80 million people worldwide. Several risk factors, especially age and elevated intraocular pressure, play crucial roles in glaucoma development . However, the exact relationship between intraocular pressure and glaucoma remains unclear; not all people with elevated intraocular pressure develop glaucoma, while even those with normal intraocular pressure can develop the disease. The only therapies that can improve or halt the deterioration of vision in patients with glaucoma are those that reduce intraocular pressure via topical instillation of anti-glaucoma eye drops, laser therapy or invasive surgery . Therapies that lower intraocular pressure within normal limits, have been estimated to slow optic nerve damage by 50–60%. ‘Omega 3 fatty acids can provide another option for optic nerve protection in patients with glaucoma ‘ said Dr Tassos Georgiou , the head of the research team at Ophthalmos Link :click for the published article

Publication ‘Omega-3 fatty acids protect retinal neurons in glaucoma mouse model’ Exp Eye Res. Jan 2018 Read More »

Publication ‘Therapeutic potential of omega-3 fatty acids supplementation in a mouse model of dry macular degeneration’, British Medical Journal, Ophthalmology, June 2017

Ophthalmos Research Team have demonstrated that omega 3 fatty acids when used at the right dosage (by testing the blood AA/EPA ratio) could be beneficial in patients with Age Related Macular Degeneration and perhaps other ocular pathologies which involve photoreceptor damage. The benefits will have a positive impact on the quality of life of patients suffering from such conditions. ‘The findings not only show promising therapeutic potential for Dry Macular Degeneration but also for other conditions which cause photoreceptor damage such as macular dystrophies’ said Dr Tassos Georgiou Consultant Ophthalmologists and the Head of the Research Team at Ophthalmos Institute. Link here for the publication

Publication ‘Therapeutic potential of omega-3 fatty acids supplementation in a mouse model of dry macular degeneration’, British Medical Journal, Ophthalmology, June 2017 Read More »

Publication ‘Neuroprotective effects of Omega 3 fatty acids in a rat model of anterior ischemic optic neuropathy’

Ophthalmos Research team in collaboration with the research team of Professor Tsai from Tzui Chi University, Taiwan have demonstrated for the first time that omega 3 polyunsaturated fatty acids have neuroprotective effects on ischemic optic neuropathies. ‘This is of clinical significance as there is no treatment for ischemic optic neuropathies’ said Dr Tassos Georgiou the head of the research department at Ophthalmos Institute. ‘ Our findings not only show promising therapeutic potential for neuroprotection of ischemic optic neuropathies but also for other conditions of optic nerve damage such as glaucoma which is the second cause of blindness. The dose is individualized for each patient and depends on the blood ratio of AA/EPA’ The potential impact of this study is highly significant. It will result in greater visual acuity and better quality of life in patients suffering from optic neuropathies. Link here to read the publication

Publication ‘Neuroprotective effects of Omega 3 fatty acids in a rat model of anterior ischemic optic neuropathy’ Read More »

Omega 3 benefits dry eye patients

Ophthalmos has a patented therapy of moderate to severe dry eyes using omega 3 therapy. ‘Omega 3 is beneficial for dry eyes when given at the correct dose and ratio of EPA to DHA. This is simply decided by using a blood test to measure the ratio of AA to EPA’ said Dr Tassos Georgiou, founder and director of Ophthalmos Research and Educational Institute who is also the patent owner in USA and Europe for using omega 3 to treat moderate to severe dry eyes. A recent multicentre double blind placebo controlled randomised study published in September 2016 confirms the results discovered by Ophthalmos. Link : http://www.ncbi.nlm.nih.gov/pubmed/27442314

Omega 3 benefits dry eye patients Read More »

Ophthalmos publishes the results of its patented treatment of ‘the role of omega 3 fatty acids for eye health’

AMD is the leading cause of visual impairment and blindness in people over the age of 50 years. The number of people with this disease is estimated at 200 million worldwide and this number is expected to increase in 20 years by 50 %.. In 2010 there was a direct healthcare systems expenditure of $255 billion associated with AMD and this is expected to increase to $294 billion dollars by the year 2020 . Although it is such a common pathology there is no treatment available for dry AMD to improve vision or even stop the progression of the disease.Ophthalmos publishes the results of using high doses of mainly EPA fatty acids on macular degenerations and dry eyes.Click here for a published summary of results

Ophthalmos publishes the results of its patented treatment of ‘the role of omega 3 fatty acids for eye health’ Read More »